Australia's Osteopore jumps on partnership for clinical R&D in China

Osteopore

08/06/2023 03:29

** Shares of Osteopore Ltd  OSX.AX  jump as much as 7.1% to
A$0.090, hitting their highest level since April 24
    ** The medical technology firm says it has signed a binding
term sheet with CellHeal, a medical technology commercialisation
group 
    ** Co says deal to work towards commercialising its
regenerative implant technology across China, Hong Kong, Macau,
and Taiwan
    ** Says CellHeal has agreed to pay its own costs in
connection with the R&D and commercialisation of the projects,
estimated to cost at least A$4 mln ($2.67 mln)
    ** Shares on track to record a third consecutive session of
gains, if trend holds  
    ** OSX stock down 43.2% YTD, as of last close 

    ($1 = 1.5008 Australian dollars)

 (Reporting by Echha Jain in Bengaluru)
 ((Echha.jain@thomsonreuters.com))